Bupivacaine

Verify with FDA CVM →

614 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
614
Total Reports
54
Deaths Reported
880.0%
Death Rate

Active Ingredients

Bupivacaine

Administration Routes

UnknownParenteralOtherSubcutaneousOralEpiduralIntraocularTopicalPerineuralIntradermal

Species Affected

Dog 222
Cat 219
Unknown 154
Human 12
Rabbit 2
Pig 2
Horse 1
Rat 1
Cephalopoda 1

Most Affected Breeds

Unknown 169
Domestic Shorthair 123
Dog (unknown) 56
Retriever - Labrador 33
Cat (unknown) 23
Domestic Longhair 22
Domestic Mediumhair 18
Retriever - Golden 14
Boxer (German Boxer) 10
Crossbred Canine/dog 7

Most Reported Reactions

Not eating 48
Vials, Damaged 37
Decreased appetite 32
Behavioural disorder NOS 31
Other abnormal test result NOS 30
Death 28
Vomiting 25
Bruising 25
Death by euthanasia 24
Dilated pupils 24
Anorexia 23
Lethargy (see also Central nervous system depression in 'Neurological') 23

Outcome Breakdown

Recovered/Normal
152 (32.8%)
Ongoing
128 (27.6%)
Outcome Unknown
124 (26.8%)
Died
31 (6.7%)
Euthanized
25 (5.4%)
Recovered with Sequela
3 (0.6%)

Data Summary

Metric Value
Total adverse event reports 614
Reports involving death 54
Case-fatality rate (reported events) 880.0%
Distinct species in reports 9
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Bupivacaine Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 614 adverse event reports referencing Bupivacaine, including 54 reports in which the animal died — a 880.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Bupivacaine. Reported administration routes include Unknown, Parenteral, Other, Subcutaneous. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Bupivacaine reports are Dog (222 reports), Cat (219 reports), Unknown (154 reports), with Dog accounting for the largest share. Within those species, Unknown (169), Domestic Shorthair (123), Dog (unknown) (56) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Bupivacaine are Not eating (48), Vials, Damaged (37), Decreased appetite (32), Behavioural disorder NOS (31). Of the 463 reports with a coded outcome, Recovered/Normal is the leading category at 32.8%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Bupivacaine.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial